DRG Epidemiology’s coverage of human papilloma virus comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of human papilloma virus for each country, as well as annualized case counts projected to the national population.

DRG Epidemiology’s human papilloma virus forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with human papilloma virus?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of human papilloma virus over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following human papilloma virus subpopulations:

  • Total prevalent cases by high-risk HPV.
  • HPV high-risk genotype proportions.

Note: coverage may vary by country.

Table of contents

  • Human Papilloma Virus - Epidemiology - Mature Markets Data
    • Introduction
      • Key Findings
        • Introduction Graphics
          • Prevalence of HPV: All Types per 100 Among People Aged 15 or Older in 2018 and 2028
          • Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of HPV over the Next Ten Years
          • Number of Additional Prevalent Cases of HPV Avoided Over the Period 2018-2028 Across the Countries Under Study
          • Proportion of High-Risk HPV Genotypes Among Total High-Risk HPV Strains
      • Epidemiology Data
      • Methods
        • Total Prevalent Cases: Any HPV
        • Total Prevalent Cases: High-Risk HPV
        • HPV Genotype Proportions (High-Risk HPV)
      • Reference Materials
        • Literature Review
          • Studies Included in the Analysis of HPV
          • Studies Excluded from the Analysis of HPV
        • Risk/Protective Factors
          • Risk/Protective Factors for HPV
        • Bibliography

    Author(s): Johnson Olabisi, MBBS, MSc; Nishant Kumar, MPH

    Johnson joined Decision Resources Group (DRG) in 2015 and with the Epidemiology team develops epidemiological populations forecasts for different infectious and non-communicable diseases with his particular interests in the oncology space.

    Prior to joining DRG, he trained as a community physician where he was involved in primary (patient) care, primary health care and various community research & activities. He has also supervised and coordinated various governmental and non-governmental public health projects. Johnson holds a Masters of Science in Public Health (Health Economics) degree from the London School of Hygiene and Tropical Medicine with a Masters in Epidemiology and Medical Statistics & a Medical degree from the University of Ibadan, Nigeria.

     

    Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects.

    His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.